title: Phase II study with oxaliplatin and S-1 for patients with metastatic colorectal cancer.
abstract: BACKGROUND
  To evaluate the efficacy and safety of the combination of oxaliplatin and S-1 (OS) in treating metastatic colorectal cancer.
  
  
  METHODS
  Eligible patients were those with measurable lesions, no previous history of chemotherapy (except adjuvant chemotherapy), an age of 18-70 years, and an Eastern Cooperative Oncology Group performance status of zero to two. Oxaliplatin 130 mg/m(2) was administered i.v. on day 1, and S-1 40 mg/m(2) b.i.d. was administered orally on days 1-14, every 3 weeks.
  
  
  RESULTS
  Forty-eight patients (median age, 56 years) were enrolled: 23 had colon cancer, seven rectosigmoid colon cancer; and 18 rectal cancer. Of the 48 patients, 31 were diagnosed with metastatic cancer and 17 had relapsed cancer after surgery, with adjuvant chemotherapy or chemoradiotherapy. In total, 413 cycles were administered (median 6 per patient; range 2-24). Toxicity was evaluated in 48 patient and response in 46. Major toxic effects were grade 3/4 thrombocytopenia (13%) and neutropenia (10%). The overall response rate was 54% [95% confidence interval (CI) 40% to 68%]. The median time to progression and median survival time were 8.5 (95% CI 6.2-10.9) months and 27.2 (95% CI 20.3-34.0) months, respectively.
  
  
  CONCLUSIONS
  These data indicate that the OS regimen is effective and well tolerated in patients with advanced colorectal cancer.
authors.affiliation: Department of Internal Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, South Korea. fhdzang@hallym.or.kr
authors.forename: D Y
authors.initials: DY
authors.lastname: Zang
authors.forename: B H
authors.initials: BH
authors.lastname: Lee
authors.forename: H-C
authors.initials: HC
authors.lastname: Park
authors.forename: H H
authors.initials: HH
authors.lastname: Song
authors.forename: H J
authors.initials: HJ
authors.lastname: Kim
authors.forename: J Y
authors.initials: JY
authors.lastname: Jung
authors.forename: J H
authors.initials: JH
authors.lastname: Kim
authors.forename: H Y
authors.initials: HY
authors.lastname: Kim
authors.forename: J H
authors.initials: JH
authors.lastname: Kwon
authors.forename: S W
authors.initials: SW
authors.lastname: Hwang
authors.forename: S R
authors.initials: SR
authors.lastname: Park
authors.forename: C H
authors.initials: CH
authors.lastname: Park
authors.forename: K O
authors.initials: KO
authors.lastname: Kim
authors.forename: M-J
authors.initials: MJ
authors.lastname: Kim
authors.forename: K M
authors.initials: KM
authors.lastname: Jang
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D000077150:Oxaliplatin; D010094:Oxonic Acid / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D004338:Drug Combinations; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid